Serialisation of prescription medicines will become
mandatory in the EU on February 9, 2019, resulting in
new labelling requirements as a prerequisite for market
access. Pharmaceutical manufacturers must therefore
invest in suitable solutions now. Simultaneously, late-stage
customisation is getting increasingly important due to
continuously decreasing batch sizes. Helmut Schneider,
Product Manager in Atlantic Zeiser‘s Pharma & Packaging
Solutions division, analyses the different steps to consider
where in the production process to most sensibly perform
serialisation. The solution chosen by the pharmaceutical
company will depend on the existing infrastructure as well
as several other factors.